PHILADELPHIA — The Pennsylvania Superior Court on Nov. 26 affirmed a $76.66 million compensatory verdict in a Risperdal gynecomastia case, in part because defendants Janssen Pharmaceuticals Inc. allegedly concealed a study that found a statistically significant risk (A.Y., et al. v. Janssen Pharmaceuticals Inc., et al., Nos. 3058 EDA 2016 and 3059 EDA 2016, Pa. Super.).
WASHINGTON, D.C. — The current manufacturer of the over-the-counter heartburn drug Zantac and three former manufacturers on Nov. 27 told a federal judicial panel that they support the creation of a Zantac/ranitidine/N-nitrosodimethylamine (NDMA) multidistrict litigation (In Re: Zantac/Ranitidine NDMA Litigation, MDL Docket No. 2924, JPMDL).
NEW YORK — The Second Circuit U.S. Court of Appeals on Nov. 25 affirmed dismissal of a breach-of-contract and fraud lawsuit against a plaintiff law firm for allegedly mishandling a plaintiff’s breast implant claim (Beverly J. Ezra v. Weitz & Luxenberg, P.C., No. 18-3742, 2nd Cir., 2019 U.S. App. LEXIS 35676).
PHILADELPHIA — Following the U.S. Supreme Court’s May 20 preemption ruling, a panel of the Third Circuit U.S. Court of Appeals on Nov. 25 remanded 507 Fosamax femur fracture cases to a multidistrict litigation court in New Jersey for determination of whether the plaintiff’s claims are preempted (In Re: Fosamax [Alendronate Sodium] Product Liability Litigation, No. 14-2813, 3rd Cir.).
New developments in the following mass tort drug and device cases are marked in boldface type.
PHILADELPHIA — In a 2-1 opinion, the Third Circuit U.S. Court of Appeals reversed summary judgment in a Zimmer metal-on-metal hip case, saying that under Pennsylvania law, whether Pennsylvania’s discovery rule applies is a question of fact for a jury (Marilyn Adams v. Zimmer US Inc. et al., No. 18-3011, 3rd Cir., 2019 U.S. App. LEXIS 34513).
PHILADELPHIA — The Pennsylvania Supreme Court on Nov. 20 vacated summary judgment in two Risperdal gynecomastia cases as being time-barred, ruling that the state Superior Court erred in determining if there was enough publicity about a cause and effect to put the plaintiffs on notice (In Re: Risperdal Litigation [Jonathan Saksek v. Janssen Pharmaceuticals, Inc., et al., No. 22 EAP 2018; Joshua Winter v. Janssen Pharmaceuticals, Inc., et al., No. 23 EAP 2018, Pa. Sup., 2019 Pa. LEXIS 6480).
PHILADELPHIA — A Pennsylvania state court judge on Oct. 30 denied without comment a Johnson & Johnson motion for him to recuse himself from a Risperdal gynecomastia case for allegedly celebrating an $8 billion punitive damages verdict with some members of the jury (Nicholas Murray v. Janssen Pharmaceuticals, Inc., et al., No. 13040199000495, Pa. Comm. Pls., Philadelphia Co.).
SYRACUSE, N.Y. — Two women on Nov. 12 filed a New York state class action complaint against the manufacturer of the pre-term pregnancy prevention drug Makena, arguing that the injectable drug is ineffective and overpriced (Teresa Faughnan, et al. v. AMAG, Inc., No. 19-1394, N.D. N.Y.).
CINCINNATI — On a 2-1 vote with a lengthy dissent, the Sixth Circuit U.S. Court of Appeals on Nov. 18 dismissed an appeal by two women who sought to enjoin opioid manufacturers from dispensing their drugs to women without a negative pregnancy test (Amanda Hanlon, et al. v. Purdue Pharma L.P., et al., No. 19-3398, 6th Cir., U.S. App. LEXIS 34350).
SAN FRANCISCO — A California federal judge on Nov. 5 granted a motion by the United States to dismiss a whistleblower lawsuit alleging that drug maker Gilead Sciences Inc. caused false claims to be submitted to Medicare and Medicaid by using drug ingredients supplied by an unregistered Chinese supplier (United States, ex rel. Jeff Campie, et al. v. Gilead Sciences, Inc., et al., No. 11-941, N.D. Calif., 2019 U.S. Dist. LEXIS 193147).
BOSTON — GlaxoSmithKline LLC (GSK) on Nov. 1 filed a citizen petition asking the Food and Drug Administration for an opinion about Zofran’s birth defect warnings, a move that plaintiffs in the multidistrict litigation in a Nov. 13 brief say is designed to delay an upcoming bellwether trial but that GSK says in its own Nov. 13 brief will help the court decided whether the plaintiff’s claims are preempted (In Re: Zofran [Ondansetron] Products Liability Litigation, MDL Docket No. 2657, No. 15-md-2657, D. Mass.).
TRENTON, N.J. — The New Jersey Supreme Court on Nov. 4 solicited comments on a motion to create a multicounty litigation for state court lawsuits alleging early failure of the Stryker Tritanium acetabular shell, a hip prosthesis component.
NEW YORK — Counsel for Zimmer Inc. on Nov. 15 asked a New York federal judge overseeing the M/L Taper hip multidistrict litigation to restore protections under Lexecon because of the plaintiffs’ alleged “mass use” of the U.S. Supreme Court jurisdictional rule to remove cases from bellwether consideration and thus “skew” the bellwether pool (In Re: Zimmer M/L Taper Hip Prothesis Products Liability Litigation, MDL Docket No. 2859, No. 10-md-2859, S.D. N.Y.).
WILMINGTON, Del. — Opioid maker Insys Therapeutics Inc. on Nov. 14 filed an amended liquidation plan with a federal bankruptcy court that addresses the company’s settlement with the United States and addresses payments for personal injury claimants and state, municipal and tribal claims (In Re: Insys Therapeutics, Inc., et al., No. 19-11292, Bkcy. Del.).
SEATTLE — A Washington federal jury on Nov. 11 found that drug maker Biogen Inc. retaliated against a saleswoman in violation of the federal False Claims Act, 31 U.S. Code § 3729, and wrongfully terminated her in violation of public policy (Danita Erickson v. Biogen, Inc., No. 18-1029, W.D. Wash., Seattle).
NORMAN, Okla. — An Oklahoma state court judge on Nov. 15 ordered Johnson & Johnson and subsidiary Janssen Pharmaceuticals Inc. to pay the state $465.02 million for the first year of a state-run opioid abuse public nuisance abatement program (Oklahoma v. Purdue Pharma L.P., et al., No. CJ-2017-816, Okla. Dist., Cleveland Co.).
NEWARK, N.J. — A federal judge in New Jersey on Nov. 12 ruled that lead plaintiffs in a securities class action lawsuit brought against a biopharmaceutical company that develops hematology and oncology therapeutics and certain of its current and former executive officers regarding their marketing and sale of the company’s fentanyl-based cancer treatment drug have failed to plead any actionable misrepresentations in making their federal securities law claims (In re Galena Biopharma Inc. Securities Litigation, No. 17-929, D. N.J., 2019 U.S. Dist. LEXIS 196297).
CHICAGO — The Seventh Circuit U.S. Court of Appeals on Nov. 12 affirmed summary judgment against a health insurer’s racketeering lawsuit against five testosterone replacement drug manufacturers, agreeing that a jury couldn’t find that the insurer or pharmacy benefits managers relied on allegedly misleading statements by the defendants (Medical Mutual of Ohio v. AbbVie Inc., et al., No. 14-8857, 7th Cir., 2019 U.S. App. LEXIS 33702).
NEW YORK — Orthopedic device maker Life Spine Inc., its founder and a vice president will pay $5.9 million to settle a false claims lawsuit that they paid kickbacks to surgeons to use Life Spine products, the U.S. attorney for the Southern District of New York announced Nov. 7 (United States, et al., ex rel. BNHT LLC v. Life Spine Inc., et al., No. 18-1311, S.D. N.Y.).